REGENXBIO Total Assets 2014-2022 | RGNX
REGENXBIO total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
REGENXBIO Annual Total Assets
(Millions of US $) |
| 2021 |
$1,114 |
| 2020 |
$708 |
| 2019 |
$498 |
| 2018 |
$544 |
| 2017 |
$199 |
| 2016 |
$173 |
| 2015 |
$221 |
| 2014 |
$3 |
| 2013 |
$3 |
REGENXBIO Quarterly Total Assets
(Millions of US $) |
| 2022-03-31 |
$1,025 |
| 2021-12-31 |
$1,114 |
| 2021-09-30 |
$800 |
| 2021-06-30 |
$836 |
| 2021-03-31 |
$879 |
| 2020-12-31 |
$708 |
| 2020-09-30 |
$541 |
| 2020-06-30 |
$450 |
| 2020-03-31 |
$464 |
| 2019-12-31 |
$498 |
| 2019-09-30 |
$509 |
| 2019-06-30 |
$529 |
| 2019-03-31 |
$519 |
| 2018-12-31 |
$544 |
| 2018-09-30 |
$515 |
| 2018-06-30 |
$336 |
| 2018-03-31 |
$317 |
| 2017-12-31 |
$199 |
| 2017-09-30 |
$209 |
| 2017-06-30 |
$224 |
| 2017-03-31 |
$224 |
| 2016-12-31 |
$173 |
| 2016-09-30 |
$196 |
| 2016-06-30 |
$206 |
| 2016-03-31 |
$215 |
| 2015-12-31 |
$221 |
| 2015-09-30 |
$227 |
| 2015-06-30 |
$0 |
| 2015-03-31 |
$0 |
| 2014-12-31 |
$0 |
| 2014-09-30 |
$0 |
| 2013-12-31 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.899B |
$0.470B |
|
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
|
